Endpoints News on Mythryl: “Can a Chinese drugmaker become Big Pharma? Hengrui is testing that…”

Can a Chinese drugmaker become Big Pharma? Hengrui is testing that idea, laying plans to move beyond dealmaking and sell its own drugs in the US and Europe as it grows into a global force.

endpoints.newsCan a Chinese drugmaker become a big pharma company? Hengrui is testing the watersWith a valuation of about $61.2 billion, Hengrui is now larger than Takeda and Bayer. But there’s still one big item on its bucket list: selling its own treatments outside of China.

28/1/26, 9:03 pm1 repost1 like

Post